Pre-market Hot Trades in US Stocks

Garden Stage is up 8.74% in pre-market trading. Based on recent key news:

1. On September 17, Garden Stage Ltd submitted a self-underwritten offering application, planning to directly issue up to 144,117,647 shares of common stock to specific investors. This move may raise market concerns about the company's future financing capabilities, driving up the stock price. Data source: SEC filings.

2. On September 15, Garden Stage Ltd completed a registered direct offering at a price of $0.034 per share, raising approximately $4.9 million in net proceeds. The funds will be used for working capital and general corporate purposes, potentially enhancing the company's operational capabilities and market positioning. Data source: Company update.

3. On September 18, the technical sentiment signal for Garden Stage Ltd indicated a sell, with a current market capitalization of $10.25 million. Nevertheless, the market's positive reaction to the company's recent financing activities may offset the impact of the technical signals. Data source: TipRanks. The financial services industry has been active recently.

Top Gainers in Pre-market US Stocks

89bio is up 84.28% in pre-market trading. Based on recent key news:

1. On September 18, Roche announced the acquisition of 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news significantly boosted 89bio's stock price. Data source: Zhitong Finance.

2. On September 18, 89bio's key drug pegozafermin is in late-stage development and is expected to become the best therapy for treating MASH. The drug's potential has attracted market attention, further driving up the stock price. Data source: Roche statement.

3. On September 18, Roche plans to accelerate the development of its experimental weight-loss drug, showing strong interest in the obesity treatment market. This strategic move has bolstered investor confidence, pushing the stock price higher. Data source: Roche statement. Mergers and acquisitions in the biopharmaceutical industry are active, and market volatility is increasing.

Aptevo Therapeutics is up 66.67% in pre-market trading. Based on recent key news:

1. On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, leading to a 57% increase in stock price. The trial tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients who are not suitable for other treatments.

2. On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months, indicating a strong market reaction to the company's news On September 17, despite facing financial challenges including declining revenue and high leverage, Aptevo's positive progress in its oncology pipeline offers potential upside for the future. The biotechnology industry is highly volatile and requires caution